PL2957292T3 - Terapia w przypadku bielactwa nabytego - Google Patents

Terapia w przypadku bielactwa nabytego

Info

Publication number
PL2957292T3
PL2957292T3 PL15170572T PL15170572T PL2957292T3 PL 2957292 T3 PL2957292 T3 PL 2957292T3 PL 15170572 T PL15170572 T PL 15170572T PL 15170572 T PL15170572 T PL 15170572T PL 2957292 T3 PL2957292 T3 PL 2957292T3
Authority
PL
Poland
Prior art keywords
vitiligo
therapy
Prior art date
Application number
PL15170572T
Other languages
English (en)
Inventor
Philippe Wolgen
Original Assignee
Clinuvel Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008901461A external-priority patent/AU2008901461A0/en
Application filed by Clinuvel Pharmaceuticals Limited filed Critical Clinuvel Pharmaceuticals Limited
Publication of PL2957292T3 publication Critical patent/PL2957292T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0616—Skin treatment other than tanning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL15170572T 2008-03-27 2009-03-27 Terapia w przypadku bielactwa nabytego PL2957292T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008901461A AU2008901461A0 (en) 2008-03-27 Therapy for vitiligo
EP09726233.1A EP2278992B1 (en) 2008-03-27 2009-03-27 Therapy for vitiligo
EP15170572.0A EP2957292B1 (en) 2008-03-27 2009-03-27 Therapy for vitiligo

Publications (1)

Publication Number Publication Date
PL2957292T3 true PL2957292T3 (pl) 2018-04-30

Family

ID=41017103

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15170572T PL2957292T3 (pl) 2008-03-27 2009-03-27 Terapia w przypadku bielactwa nabytego

Country Status (13)

Country Link
US (3) US20110130705A1 (pl)
EP (2) EP2278992B1 (pl)
CA (1) CA2719707C (pl)
DK (1) DK2957292T3 (pl)
ES (2) ES2656131T3 (pl)
HR (1) HRP20180069T1 (pl)
HU (1) HUE038611T2 (pl)
NO (1) NO2957292T3 (pl)
NZ (1) NZ588213A (pl)
PL (1) PL2957292T3 (pl)
PT (1) PT2957292T (pl)
SI (1) SI2957292T1 (pl)
WO (1) WO2009118191A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110130705A1 (en) 2008-03-27 2011-06-02 Clinuvel Pharmaceuticals Limited Therapy for vitiligo
CA2822746A1 (en) * 2009-12-21 2011-06-30 Sarah Bacus Compositions and methods for treatment of vitiligo
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
WO2013024487A1 (en) 2011-08-16 2013-02-21 SALAFIA Elizabeth Anti- vitiligo composition
FR2984167B1 (fr) * 2011-12-16 2014-01-17 Galderma Res & Dev Association d'un agoniste des recepteurs des prostaglandines et d'un agoniste du recepteur mc1r pour le traitement et/ou la prevention de desordres de la pigmentation
US9610461B2 (en) * 2012-03-15 2017-04-04 Galderma Research & Development Combination of a MC1R receptor agonist and UVB for the treatment and/or prevention of pigmentation disorders
WO2015063102A1 (en) * 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh analogues for use in bullous disease
WO2015063099A1 (en) * 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh analogues for use in the treatment of hailey-hailey disease
EP2875806A1 (en) * 2013-11-20 2015-05-27 Infinitec Activos, S.L. Targeted capsules for the delivery of whitening agents in the skin
US20250058141A1 (en) 2021-12-17 2025-02-20 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Moderate uv-b exposure as a dietary restriction mimetic

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457864A (en) * 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
ATE84420T1 (de) 1986-02-03 1993-01-15 University Patents Inc Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
ATE109793T1 (de) 1987-05-22 1994-08-15 University Patents Inc Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung.
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5049547A (en) * 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US6251100B1 (en) 1993-09-24 2001-06-26 Transmedica International, Inc. Laser assisted topical anesthetic permeation
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
AU4004699A (en) 1998-05-15 1999-12-06 Quark Biotech, Inc. Mechanical stress induced genes, expression products therefrom, and uses thereof
WO2003072072A1 (en) * 2002-02-26 2003-09-04 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method of stimulation of melanin production and induction of skin tanning
US20040009170A1 (en) 2002-07-10 2004-01-15 Stafano Gatti Alpha-melanocyte stimulating hormone peptides protection in organ transplantation
US9345911B2 (en) 2004-08-04 2016-05-24 Clinuvel Pharmaceuticals Limited Methods of inducing melanogenesis in a subject
EP1781264B1 (en) * 2004-08-04 2013-07-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
JP5449673B2 (ja) 2004-10-08 2014-03-19 クリヌベール、ファーマスーティカルズ、リミテッド 対象者におけるメラニン形成を誘導するための組成物および方法
MX2009000434A (es) 2006-07-11 2009-01-29 Qps Llc Composiciones farmaceuticas para la distribucion de liberacion sostenida de peptidos.
WO2008025094A1 (en) * 2006-08-31 2008-03-06 Clinuvel Pharmaceuticals Limited Method of treatment of photodermatoses
FR2907682B1 (fr) * 2006-10-26 2012-12-07 Vincience Composition cosmetique et/ou pharmaceutique comprenant comme principe actif au moins un peptide et utilisation de ce peptide.
FR2907681B1 (fr) * 2006-10-26 2012-10-19 Vincience Composition pharmaceutique et/ou cosmetique contenant des polypeptides ou des peptides.
US20110130705A1 (en) 2008-03-27 2011-06-02 Clinuvel Pharmaceuticals Limited Therapy for vitiligo

Also Published As

Publication number Publication date
US11622994B2 (en) 2023-04-11
CA2719707A1 (en) 2009-10-01
ES2656131T3 (es) 2018-02-23
NO2957292T3 (pl) 2018-05-12
EP2278992A2 (en) 2011-02-02
AU2009228664A1 (en) 2009-10-01
EP2278992B1 (en) 2015-07-22
CA2719707C (en) 2018-12-04
EP2957292A1 (en) 2015-12-23
SI2957292T1 (en) 2018-04-30
NZ588213A (en) 2012-10-26
WO2009118191A3 (en) 2009-12-03
US20110130705A1 (en) 2011-06-02
DK2957292T3 (en) 2018-01-22
EP2957292B1 (en) 2017-12-13
PT2957292T (pt) 2018-02-09
HRP20180069T1 (hr) 2018-04-20
WO2009118191A2 (en) 2009-10-01
ES2550160T3 (es) 2015-11-04
US20180008676A1 (en) 2018-01-11
HUE038611T2 (hu) 2018-10-29
US20130203670A1 (en) 2013-08-08
US9801924B2 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
IL206654A0 (en) Combination therapy
PL2308885T3 (pl) Nowe związki i sposoby leczenia
GB0813740D0 (en) Therapeutic compounds
GB0806794D0 (en) Therapeutic compounds
GB0804755D0 (en) Therapeutic compounds
PT2957292T (pt) Terapia de vitiligo
GB0817121D0 (en) Anti-fungal therapy
GB0719518D0 (en) Therapy
GB0803948D0 (en) Combination therapy
GB0916997D0 (en) Combination therapy
GB0809046D0 (en) Cancer treatment
GB0716072D0 (en) Therapy
GB0700635D0 (en) Therapy
AU2008901461A0 (en) Therapy for vitiligo
GB0813292D0 (en) Therapy
GB0812659D0 (en) Therapy
GB0819642D0 (en) New therapy
GB0819645D0 (en) New therapy
GB0819643D0 (en) New therapy
GB0819644D0 (en) New therapy
GB0822908D0 (en) Vitiligo cure
GB0811850D0 (en) Therapeutic compounds
GB0815700D0 (en) Therapeutic compounds
GB0821817D0 (en) Therapeutic compounds
GB0816707D0 (en) Therapeutic compounds